GLP-1s Versus DPP-4s and Risk of Dementia in Patients Requiring Hemodialysis: A Target Trial Emulation Study
Main finding · DementiaResult — go to the resultIPTW-sHR 0.82 95% CI 0.67–0.98Authors' conclusion
In patients with diabetes requiring hemodialysis, GLP-1s (vs. DPP-4s) may be a promising therapy to reduce the risk of dementia.
Study context
- Population
- Individuals with both diabetes and hemodialysis dependence, U.S. Renal Data System and Medicare Parts A, B, and D claims 2011–2021; after inverse probability of treatment weights (IPTW) average age 63 years, 63% White, mean BMI 31 kg/m²2,014 dementia diagnoses
- Participants
- 3,619 vs 11,502
- Comparison
- GLP-1s vs DPP-4s
- GLP-1sn = 3,619
- DPP-4sn = 11,502reference
- Outcome
- Incident dementia
- Follow-up
- Median 1.5 (0.6-2.9) years
Methodological detailsactive comparator, new-user design, inverse probability of treatment weights (IPTW), Fine-Gray models accounting for competing risks of death and kidney transplantation
- Active comparator, new-user design
- Inverse probability of treatment weights (IPTW)
- Fine-Gray models accounting for competing risks of death and kidney transplantation
Main finding
Dementia
IPTW-sHR
0.82
95% CI 0.67–0.98
GLP-1svs DPP-4s
IPTW-sHR 0.82 (95% CI 0.67–0.98)
As reported in the abstract
Further findings
Cumulative incidence of dementia · 2 years · intention-to-treat analysis
As-treated and subgroup analyses
- As-treated and subgroup analyses were consistent
Safety
| Outcome | sHR (95% CI) | |
|---|---|---|
| KetoacidosisIncreased risk with GLP-1s | 1.52 (1.14–2.02) | |
| 0.512Subdistribution hazard ratio (log scale) |
Original publication
GLP-1s Versus DPP-4s and Risk of Dementia in Patients Requiring Hemodialysis: A Target Trial Emulation Study. Diabetes Care. Published 13 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →